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INTRODUCTION 
Oral administration is conventional to be leading route of 
drug delivery. More than 50% of drug delivery systems 
(DDSs) reachable in the market are oral DDSs. These 
dosage forms are easy to manage and increase patient 
compliance However the growth  of such systems is 
prohibited by several physiological difficulties. In truth 
orally administered dosage forms are exposed to broad 
range of greatly variable conditions during their transit 
throughout the gastrointestinal tract1 .Usually oral dosage 
forms are classified as a single unit and multiple unit 
dosage forms . Multiparticulate dosage forms are getting 
a huge concentration as alternative drug delivery system 
for the oral route of administration, even when the single 
unit dosage forms have been broadly used for decades. 
The most usually used pharmaceutical solid dosage 
forms today include granules, pellets, tablets and 
capsules, out of which tablets being the most popular 
dosage form, accounting for 70% of all moral 
pharmaceutical preparations produced 2. But presently it 
was sensed that some of the formulating and clinical 
problems (free flowing property, dose dumping, 
dysphagia, etc.) comes along with the single dose 
formulations. This presently leads to the dividing of 
monolithic dosage forms into multiples. Multiple unit 
dosage forms (MUDFs) or multiparticulates, are 
formulated as granules, pellets, or mini tablets (1mm in 
diameter)3. The concept of this multiple unit dosage form  
solves several formulating problems and with a common 
approach to organize the release of drug as showing the 
reproducible release profiles when compared to single 
unit dosage forms. These MUDFs, can either be filled in 
to hard capsules or compressed into bigger tablets or can 
be dispensed in a dose pouches or packets. The most 
increasingly interesting area in the development of 
MUDF'S is incorporated into tablets instead of hard 
gelatin capsules in order to make it more economical for 
the consumers and gaining more attention currently4.  
The improvement of multiparticulate drug delivery 
systems such as mini tablets, spheroids is a promising 
area in pharmaceutical research concerned with a high 
control over the release rate of drug combined with a 
high flexibility on the modification of both the initial 
dose and the loading for maintaining the release of the 
drug to get steady therapeutic level5. Extended release 
products plan on releasing the drug continuously at a 
programmed rate in order to increase the patient 
compliance. 
 
*Corresponding Author:  
Harikrishna. Jilakara,  
Asst. prof, Department of pharmaceutics, Jyothismathi college 
of pharmacy,Thurkapally(V),  Shameerpet (M), R.R-Dist.(A.P)-
500078, Email:  jilakarahari@gmail.com
 
ABSTRACT 
The objective of the present work was attempted to formulate a dual release drug delivery system comprising immediate release 
and delayed release pattern using solid dispersion and pellets of diclofenac potassium and to achieve a customized in vitro 
profile for developed formulation. Diclofenac potassium is chosen as a model drug, as it is classified under BCS-II with low 
solubility, an attempt was made to increase solubility with solid dispersion. Lactose is selected as a carrier. Solid dispersion is 
made with concentrations of carrier ratios (1:1,1:2,1:3,1:4,1:5). It was evident that in vitro drug release of the optimised batch 
(SD4) shows promising increase of solubility same is taken for the further studies to prepare a dual release dosage form as a  
immediate release formulation. Sustain release spheroids was formulated with different concentrations of polymer HPMC K 
100M.The results revealed that all the values are within the range formulation D3 was selected as an ideal batch for further 
studies to prepare a dual release dosage form as a sustained release formulation based on the in vitro performance. The dual 
release dosage form was constructed using the optimized batches from solid dispersion (SD4) and pellets (D3). The prepared 
dual release dosage form was evaluated for in vitro release studies The release models were plotted in the dual release dosage 
form .It was observed that the developed dual release  spheroids follow first order kinetics obeying fickian diffusion.  
Keywords: Pellets, Solid dispersion, Diclofenac potassium, HPMC 
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This is estimated since the incidence of administration is 
reduced and peaks are cut to prevent high concentrations, 
locally or systemically, which can cause undesirable side 
effects. At the same time the dosage forms developed 
have following novelties improving GIT absorption, 
minimize local irritation, offers a high degree of 
flexibility, and reduces the dose dumping. 
The main objective of the present work was to produce a 
dual release delivery system combining a fast release 
together with the slow release spheroids of the 
Diclofenac potassium. The further goal of the study was, 
to evaluate the in vitro release behavior for the developed 
dual release formulation. 
MATERIALS AND METHODS 
Diclofenac potassium was obtained gift sample from 
Karnataka antibiotics, Bangloore. HPMC K100M, 
Avicel PH 101, Lactose, Aerosil, Sodium hydroxide, 
Dichloromethane, Methanol was purchased from S.D 
Fine chem..Ltd, Mumbai, India. 
Formulation of diclofenac potassium solid dispersion 
Diclofenac potassium solid dispersions were prepared by 
solvent evaporation method using lactose as carrier at 
different ratios. The drug and carrier were dissolved in a 
mixture of dichloromethane and methanol (1:1 vol/vol) 
and triturated in dry mortar until the solvent is 
evaporated. The resultant solid dispersion was scraped 
out with a spatula, pulverized in a mortar and pestle. 
Stored in an airtight container for further analysis. The 
compositions of different batches are shown in Table  1.
 
Table 1: compositions of different batches 
 
 
 
 
 
 
Formulation of diclofenac potassium pellets  
The required quantity of MCC as spheronization 
enhancer, HPMC as polymeric material and diclofenac 
sodium as model drug were weighed, to this mixture 
sufficient quantity of water as granulating agent was 
added to get a wet mass6.The solid blend passed through 
the extruder model RRE/EXT-65/037 to form extrudates. 
The formed extrudates were introduced into the 
spheronizer model RRE/SPH-150/010 to get spherical 
pellets by varying different spheronization speed shown in 
Table 2. 
 
Table 2: different concentrations of HPMC used in the formulation 
Batch 
code 
DRUG 
(gm) 
HPMC 
(gm) 
 
MCC 
PH 101 
Granulating fluid 
(ml) 
D1 8 2 20.5 15 
D2 8 3.5 19 15 
 
Preparation of dual release dosage form  
The dual release dosage form was constructed using the 
optimized batches from solid dispersion (SD4) and 
pellets (D3). The amount of pellets equivalent to 100mg 
of Diclofenac and the amount of solid dispersion 
equivalent to 50mg were filled in a gelatin capsule (size 
2 ) the prepared dual release dosage form were evaluated 
for in vitro experiments .  
Characterization of diclofenac solid dispersion 
Solubility studies 
Take clean and washed amber coloured volumetric flasks 
and then dry it in oven. The Excess amount of the drug 
was added to 10ml of the selected solvents such as water, 
6.8 phosphate buffer.The solutions were kept in an 
isothermal shaker for 24 hours at 37oC. After 24 hours, 
the solutions were centrifuged, the supernatant was taken 
and assayed by UV/VISIBLE spectrophotometer. Further 
the concentration of the drug is obtained using following 
formula.  
Concentration of drug (µg/ml) = Absorbance/ slope × 
dilution factor 
In vitro drug release studies  
In vitro release profile of solid dispersion and pure drug 
were performed using USP XXII type 2 dissolution 
apparatus (TDP-06P, Electro lab, Mumbai, India). 
Sample equivalent to 50 mg of diclofenac was filled in to 
capsules and subjected to in vitro dissolution study using 
900 ml phosphate buffer pH 6.8 maintained at 37± 0.5ºC 
with a stirring speed of 50 rpm. Aliquot of 5ml was 
withdrawn at predetermined time intervals of 0, 5, 10, 
15, 20, 30, 45, 60 and 90 min. The withdrawn volume 
was replaced with the same volume of dissolution 
medium to maintain the sink condition7.The absorbance 
of the samples was measured at 282 nm using UV 
spectrophotometer. The results shown in Table 3.
S.NO Drug to carrier ratio Code of solid dispersion 
1 1:1 SD-1 
2 1:2 SD-2 
3 1:3 SD-3 
4 1:4 SD-4 
5 1:5 SD-5 
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Table 3: In vitro dissolution studies of solid dispersion formulations 
 
In Vitro Dissolution Studies for Pellets  
A quantity of pellets and which will be theoretically 
contain a drug content of 100mg Diclofenac was filled in 
the capsules and subjected to in vitro dissolution study 
using USP XXII model type II (paddle). 900ml of 
phosphate buffer pH 6.8 was transferred to each jar and 
placed them in a test assembly which is maintained at 
37°C.  
Table 4: In vitro Dissolution Profile of Diclofenac potassium 
pellets of D-1 to D-3 with different concentration of polymer 
TIME  
Percentage cumulative release 
DI %CLR D2 %CLR D3  %CLR 
0  0 0 0 
0.083  31.75±1.7 18.52±0.6 7.07±1.3 
0.42  48.12±0.3 24.65±0.1 17.9±1.9 
0.74  58.11±0.8 35.96±0.8 27.9±1.5 
2  80.46±1.3 45.78±1.6 32.7±2.9 
3  
 
52.83±1.3 36.4±1.9 
4  
 
65.98±1.8 43.7±2.1 
5  
 
72.56±0.5 47.5±1.0 
6  
 
84.87±1.1 52.6±1.2 
7  
  
56.8±0.4 
8  
  
63.5±1.7 
10  
  
68.6±0.8 
12  
  
83.3±1.4 
 
The capsules were placed in the jar and the assembly was 
brought down to static position8. 
The medium was stirred at 50 rpm. 5ml of samples were 
withdrawn at different time intervals up to 12 h (0.083, 
0.42, 0.74, 2, 3, 4, 5, 6, 7, 8, 10 and 12). Equal quantity 
of fresh medium was replaced after each sampling. The 
sample was diluted to 10 times and absorbance was 
measured at 282 nm. The results shown in Table 4. 
Drug release kinetics 9,10 :  
 In order to investigate the mode of release data were fitted 
into zero-order, first-order, Higuchi, Korsmeyer-Peppas 
equations .The regression equations were calculated and 
the correlation coefficients were determined. 
 
RESULTS AND DISCUSSION 
Infrared spectroscopy  
The FTIR spectra of the drug with polymer and 
excipients (HPMC, MCC, and lactose) showed there was 
no major shifting, loss or appearance of functional peaks 
between the spectra of drug, physical mixture of drug and 
excipients. It is concluded that the drug and excipients 
were compatible with each other without any chemical 
interaction. Figure 1. 
 
 
                                         Figure:1(a) FTIR of HPMC                      Figure:1 (b) FTIR of Lactose 
 
Figure:1(c)FTIR of Diclofenac      Figure:1(d)FTIR of Diclofenac+hpmc+lactose 
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TIME 
(min) 
PURE DRUG SD-1 SD-2 SD-3 SD-4 SD-5 
0  0  0  0  0  0  0  
15  15.693±1.0  19.56±1.7  23.987±1.5  21.954±0.1  31.752±0.8  26.897±0.9  
30  26.557±1.1  29.897±1.8  39.123±1.3  52.137±0.2  69.836±0.7  54.876±0.7  
60  34.567±1.3  48.987±1.7  47.657±1.9  65.453±0.3  72.815±0.5  68.356±0.5  
120  40.887±1.4  68.908±1.6  72.98±1.7  78.787±0.4  84.568±0.3  73.765±0.3  
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Differential Scanning Calorimetry  
The DSC thermogram of diclofenac potassium exhibited an 
endothermic peak o at 286.48 OC, which corresponds to 
the melting Point of diclofenac potassium. The carrier 
lactose showed an endothermic peak at 217.66 O C which 
corresponds to the melting point of lactose .There was only 
one endothermic peak observed for solid dispersions 
prepared using drug: carrier ratio, 1:4 at 217.66 OC. which 
corresponds to the melting of  lactose . The disappearance 
of endothermic peak of drug (Diclofenac potassium) in 
solid dispersion gives an idea that diclofenac might be in 
dissolve state in melted lactose. This could be attributed to 
higher lactose concentration and uniform distribution of 
drug in the crust of lactose resulting in complete miscibility 
of molten drug in lactose. The disappearance of 
endothermic peak in solid dispersion formulations confirms 
the amorphous state of drug in prepared solid dispersion 
formulations. Figure 2. 
 
         
 
Figure 2(a): DSC of Diclofenac potassium                        
 
Figure 2(b): DSC Of Lactose 
 
Figure 2(c): DSC of Diclofenac potassium+ Lactose 
Drug content of solid dispersions  
Percent drug content of various solid dispersion 
formulations i.e. SD1, SD2, SD3, SD4,and SD5 were 
found to be 95.9%, 97.4%, 96.8%, 97.9%, and 96.7%, 
respectively. The dissolution behavior of Diclofenac 
potassium from various SD formulations and the pure 
drug in PBS (pH 6.8) was examined in comparison with 
the intact drug by plotting the percentage of drug 
released against time  shown in Figure 3. The drug 
release from different SD formulations prepared by 
solvent evaporation method followed the order: SD4 > 
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SD5 > SD3 > SD2 > SD1. It is evident that the rate of 
dissolution of pure drug is very low, only 40.8 % of the 
drug being dissolved within 2 h. Dispersion of the drug 
in the hydrophilic carrier's considerably enhanced 
dissolution compared to the pure drug. This was 
supposed to be due to the effect of  molecular dispersion 
of the drug in lactose, and the decreased crystallinity of 
diclofenac potassium existing in SDs. 
The dissolution rate of the solid dispersion formulations 
was higher compared to pure diclofenac potassium. 
From the In vitro drug release profile for different SD 
formulation, it is evident that amongst the SD 
formulated, there was an increase in dissolution up to 
the ratio 1:4, but after this there is no significant 
increase in the dissolution of the drug. This might be due 
to complete dispersion of drug with lactose at 1:4 ratio. 
Further, increase in carrier concentration, a decrease in 
dissolution rate was observed. This might be due to 
formation of the viscous boundary layer around the drug 
particles, leading to decrease in the dissolution rate. So, 
formulation SD4 was selected for further studies. 
Possible mechanisms of increased dissolution rates of 
drug in solid dispersions could be improved wettability 
and dispersibility of drug from the dispersion, 
solubilization effect of the carrier, absence of the 
aggregation of drug, reduction of drug crystallinity, 
dissolution of the drug in the hydrophilic carrier and 
conversion of the drug to the amorphous state. The results 
are shown in Table  5. 
 
Table 5: Comparison of In vitro drug release of optimized dual release formulation (pellets) with marketed 
formulations 
TIME 
(h) 
MARKETED 
IR 
SOLID 
DISPERSION 
MARKETED 
SR 
D3 IR + SR 
(% CR)(H5) 
IR + SR 
(AMOUNT CR) 
0 0 0 0 0 0 0 
0.083 21.642±0.6 31.752±0.8 1.39±0.9 7.07±1.3 16.54±0.9 24.812 
0.42 43.1284±0.7 69.836±0.7 3.85±1.0 17.9±1.9 37.29±1.4 55.936 
0.74 49.1148±0.8 72.815±0.5 8.84±1.1 27.9±1.5 59.61±1.8 89.415 
2 76.4672±0.9 84.568±0.3 10.66±1.5 32.7±2.9 64.24±0.3 96.368 
3   14.01±1.3 36.4±1.9 68.6±1.1 102.9 
4   17.98±1.2 43.7±2.1 74.06±1.2 111.1 
5   20.58±0.5 47.5±1.03 79.8±0.5 119.7 
6   32.63±1.6 52.6±1.2 81.8±1.9 122.7 
7   38.55±1.3 56.8±0.4 85.6±1.6 128.4 
8   49.02±1.8 63.5±1.7 88.26±0.4 132.4 
10   53.60±1.0 68.6±0.8 90.26±0.9 135.4 
12   59.53±1.8 83.3±1.4 94.73±0.5 142.1 
 
 
 
Figure 3: In vitro drug release studies of solid dispersion and spheroids 
Drug release kinetics:  
In order to investigate the mode of release data were fitted into zero-order, first-order, Higuchi, Korsmeyer-Peppas 
equations Figure 4-7. .The regression equations were calculated and the correlation coefficients were determined and shown 
in Table 6. 
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Figure 4: Zero order kinetics     
             
 
Figure 5: First order kinetics 
 
 
Figure 6: Hieguchi plot 
 
 
Figure 7: Peppa”s  plot 
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Table 6: Regression Co-Efficient of Zero order, First order, Higuchi and Peppa's 
Name of the 
formulation  
Zero order  First order  Higuchi  
Peppa’s  
R2  N  
Pellets  0.6882  0.9482  0.8858  0.925  0.320  
 
CONCLUSION 
From the experimental results it can be concluded that the 
dual release dosage form was constructed using the 
optimized batches from solid dispersion (SD4) and 
pellets (D3). As evident from the in vitro release studies 
the dual release spheroids combine the advantages of both 
IR and SR formulations. Thus the absorption lag time 
associated with SR formulations could be minimized using 
these formulations. The developed  dual release system can 
able to deliver a first fraction of the dose in short time (a 
few minutes) and to deliver a second fraction for a longer 
period of time at a constant rate to overcome significant 
daily drug concentration variation reference to single unit 
conventional drug delivery systems and to improve patient 
compliance.
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